Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Abstract
Cannabidiol (CBD) is a major non-psychotomimetic component of Cannabis sativa that has been shown to have an anxiolytic effect in human and animal models. Earlier studies suggest that these effects involve facilitation of serotonin, a neurotransmitter that has also been related to obsessive-compulsive disorder. On the basis of this evidence, this study investigated the effects of CBD in C57BL/6J mice submitted to the marble-burying test (MBT), an animal model proposed to reflect compulsive behaviour. CBD (15, 30 and 60 mg/kg) induced a significant decrease in the number of buried marbles compared with controls (34, 41 and 48%, respectively). A similar, although larger, decrease was also found after the serotonin selective reuptake inhibitor paroxetine (10 mg/kg, 77% decrease) and the benzodiazepine diazepam (2.5 mg/kg, 84% decrease). The effect of CBD (30 mg/kg) was still significant after 7 days of daily repeated administration, whereas the effect of diazepam disappeared. Pretreatment with WAY100635 (3 mg/kg), a 5HT1A receptor antagonist, prevented the effects of paroxetine but failed to alter those of CBD. These latter effects, however, were prevented by pretreatment with the CB1 receptor antagonist AM251 (1 mg/kg). These results indicated that CBD and paroxetine decrease the number of buried marbles in the MBT through distinct pharmacological mechanisms. They also suggest a potential role of drugs acting on the cannabinoid system in modulating compulsive behaviour.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Systemic administration of CBD in mice exerts anxiolytic-like effects in the marble-burying test.
“marble-burying test (in mice) (Casarotto et al., 2010)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Casarotto et al., 2010
The acute effects of CBD in the marble burying test and aversive memory reconsolidation were prevented by CB1-receptor antagonists.
“Indeed, the acute effects of CBD in the marble burying test and aversive memory reconsolidation were prevented by CB1-receptor antagonists (24, 26).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [26]
Cites
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · see citing works
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · see citing works
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315 · see citing works
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002 · see citing works
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · see citing works
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 851 · see citing works
Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety
Thomas, A., Burant, A., Bui, N., Graham, D., Yuva-Paylor, L. A., & Paylor, R. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1466-y · Cited by 698 · see citing works
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497 · see citing works
Evaluation of marble-burying behavior as a model of anxiety
Njung'e, K., & Handley, S. L. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90590-x · Cited by 487 · see citing works
Eddy, K. T., Dutra, L., Bradley, R., & Westen, D. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.08.004 · Cited by 475 · see citing works
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366 · see citing works
Self-citationCampos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · see citing works
Self-citationGlutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · see citing works
Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 312 · see citing works
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1521 · Cited by 301 · see citing works
Broekkamp, C. L., Rijk, H. W., Joly-Gelouin, D., & Lloyd, K. L. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90051-8 · Cited by 286 · see citing works
Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283 · see citing works
Self-citationde Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 264 · see citing works
Pittenger, C., Krystal, J. H., & Coric, V. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.006 · Cited by 223 · see citing works
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207 · see citing works
Self-citationGrant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197 · see citing works
Ichimaru, Y., Egawa, T., & Sawa, A. (1995) · Japanese Journal of Pharmacology · doi:10.1254/jjp.68.65 · Cited by 163 · see citing works
Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
Aboujaoude, E. N., Barry, J. J., & Gamel, N. N. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e9a4 · Cited by 137 · see citing works
Schaun Korff, A., & Harvey, B. H. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.007 · Cited by 123 · see citing works
The psychobiology of anxiolytic drugs
Argyropoulos, S. V., Sandford, J. J., & Nutt, D. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00083-8 · Cited by 117 · see citing works
Carlsson, M. L. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102006401.x · Cited by 96 · see citing works
Egashira, N., Okuno, R., Harada, S., Matsushita, M., Mishima, K., Iwasaki, K., Nishimura, R., Oishi, R., & Fujiwara, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.035 · Cited by 95 · see citing works
Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers.
Zuardi, A. W., Guimarães, F. S., & Moreira, A. C. (1993) · PubMed · Cited by 76 · see citing works
Self-citationEndocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors
Umathe, S. N., Manna, S. S. S., Utturwar, K. S., & Jain, N. S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.020 · Cited by 66 · see citing works
Umathe, S. N., Bhutada, P., Jain, N. S., Mundhada, Y. R., Borkar, S. S., & Dhumal, B. (2009) · Nitric Oxide · doi:10.1016/j.niox.2009.07.001 · Cited by 54 · see citing works
Improvement in Refractory Obsessive Compulsive Disorder With Dronabinol
Schindler, F., Anghelescu, I. G., Regen, F., & Jockers-Scherübl, M. C. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07061016 · Cited by 42 · see citing works
Egashira, N., Okuno, R., Matsushita, M., Abe, M., Mishima, K., Iwasaki, K., Nishimura, R., Oishi, R., & Fujiwara, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.100 · Cited by 41 · see citing works
Effects of agents targeting glutamatergic systems on marble-burying behavior
Iijima, M., Kurosu, S., & Chaki, S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.12.048 · Cited by 28 · see citing works
Treatment duration of obsessive compulsive disorder
Dolberg, O. T., lancu, I., & Zohar, J. (1996) · European Psychiatry · doi:10.1016/s0924-9338(97)82578-3 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Self-citationCampos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001502 · Cited by 313 · see citing works
Self-citationTranslational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Self-citationGarcía-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Self-citationOn disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment
Stern, C. A. J., Gazarini, L., Takahashi, R. N., Guimarães, F. S., & Bertoglio, L. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.63 · Cited by 156 · see citing works
Self-citationSartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.033 · Cited by 156 · see citing works
Self-citationCampos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139 · see citing works
Self-citationSchiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.017 · Cited by 135 · see citing works
Self-citationGomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89 · see citing works
Self-citationCampos, A. C., de Paula Soares, V., Carvalho, M. C., Ferreira, F. R., Vicente, M. A., Brandão, M. L., Zuardi, A. W., Zangrossi, H., & Guimarães, F. S. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2878-7 · Cited by 65 · see citing works
Gomes, F. V., Alves, F. H. F., Guimarães, F. S., Correa, F. M. A., Resstel, L. B. M., & Crestani, C. C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.09.007 · Cited by 27 · see citing works
Treatment Resistance in Obsessive-Compulsive Disorder
Middleton, R., Wheaton, M. G., Kayser, R., & Simpson, H. B. (2019) · Treatment Resistance in Psychiatry · doi:10.1007/978-981-10-4358-1_11 · Cited by 19 · see citing works
The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics
Ahmed, M., Boileau, I., Le Foll, B., Carvalho, A. F., & Kloiber, S. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1926 · Cited by 11 · see citing works
- Authors
- Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S.
- Affiliations
- Universidade de São Paulo (BR)
- Corresponding author
- Casarotto, Plinio C.
- Venue
- Behavioural Pharmacology
- Published
- 2010-07
- Volume
- 21
- Issue
- 4
- Pages
- 353-358
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W1979642301
- Cited by
- 141
- References
- 35
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 12 · 2023: 10 · 2022: 13 · 2021: 7 · 2020: 13 · 2019: 7 · 2018: 13 · 2017: 13 · 2016: 8 · 2015: 8 · 2014: 2 · 2013: 7 · 2012: 12
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Behavioural Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Keywords
- cannabidiol, compulsive behaviour, obsessive-compulsive disorder, CB1 receptor, serotonin, 5-HT1A receptor, paroxetine, diazepam, anxiolytic effects, endocannabinoid system, repeated administration
- MeSH terms
- Animals, Behavior, Animal, Cannabidiol, Diazepam, Dose-Response Relationship, Drug, Hypnotics and Sedatives, Male, Mice, Inbred C57BL, Motor Activity, Synaptic Transmission, Piperazines, Piperidines, Pyrazoles, Pyridines, Serotonin Antagonists, Selective Serotonin Reuptake Inhibitors, Paroxetine, Receptor, Cannabinoid, CB1, Receptor, Serotonin, 5-HT1A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
